FOLH1 and neoplasm: Despite potential changes of liver 68Ga-PSMA11 uptake during 177Lu-PSMA therapy upon shifts of biodistribution depending on tumor sink effect, the use of liver as the reference organ to threshold malignancy comparing subsequent timepoints is feasible [19].